Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for TARS

Stock Name	Tarsus Pharmaceuticals Inc
Ticker	TARS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US87650L1035

Show aggregate TARS holdings

News associated with TARS

Blair William & Co. IL Trims Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Blair William & Co. IL decreased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 58.1% during the first quarter, Holdings Channel reports. The fund owned 11,416 shares of the company’s stock after selling 15,814 shares during the period. Blair William & Co. IL’s holdings in Tarsus Pharmaceuticals were worth $586,000 […] - 2025-08-11 05:52:54
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Brokerages: Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have earned a consensus rating of “Buy” from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-08-06 03:06:50
Arizona State Retirement System Buys 470 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Arizona State Retirement System lifted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 6.1% during the first quarter, Holdings Channel.com reports. The firm owned 8,182 shares of the company’s stock after acquiring an additional 470 shares during the period. Arizona State Retirement System’s holdings in Tarsus Pharmaceuticals were worth $420,000 […] - 2025-07-23 05:44:46
Brokerages Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $66.67: Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-06-20 02:36:52
GAMMA Investing LLC Purchases 13,115 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): GAMMA Investing LLC grew its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 36,430.6% in the first quarter, Holdings Channel reports. The fund owned 13,151 shares of the company’s stock after acquiring an additional 13,115 shares during the quarter. GAMMA Investing LLC’s holdings in Tarsus Pharmaceuticals were worth $676,000 at the end of […] - 2025-06-19 04:06:59
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 18.7% during the fourth quarter, HoldingsChannel reports. The fund owned 69,826 shares of the company’s stock after acquiring an additional 10,991 shares during the quarter. UBS AM a distinct […] - 2025-06-05 06:14:53
Nuveen Asset Management LLC Has $6.95 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Nuveen Asset Management LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 10.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,539 shares of the company’s stock after selling 15,186 shares during the quarter. Nuveen Asset […] - 2025-05-30 05:04:50
Tarsus Pharmaceuticals (NASDAQ:TARS) Raised to Buy at HC Wainwright: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) was upgraded by equities research analysts at HC Wainwright to a “buy” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $72.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 71.22% from the […] - 2025-05-29 02:15:10
Two Sigma Advisers LP Has $2.96 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Two Sigma Advisers LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 79.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,500 shares of the company’s stock after selling 202,900 shares during the quarter. Two Sigma […] - 2025-05-28 07:09:12
Two Sigma Investments LP Has $5.05 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Two Sigma Investments LP lowered its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,171 shares of the company’s stock after selling 204,832 shares during the quarter. […] - 2025-05-28 05:04:57
Tarsus Pharmaceuticals (NASDAQ:TARS) and Dyadic International (NASDAQ:DYAI) Critical Survey: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends. Earnings and Valuation This table compares Tarsus […] - 2025-05-27 02:17:08
Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $66.33: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has earned an average recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-05-26 03:08:58
Dimensional Fund Advisors LP Cuts Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Dimensional Fund Advisors LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 15.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 341,305 shares of the company’s stock after selling 62,658 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Tarsus Pharmaceuticals were worth $18,897,000 at […] - 2025-05-08 05:25:05
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock: Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) had its target price upped by investment analysts at The Goldman Sachs Group from $46.00 to $51.00 in a report released on Monday,Benzinga reports. The firm currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 9.80% from […] - 2025-05-07 02:22:52
Barclays PLC Sells 23,999 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Barclays PLC trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 24.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,664 shares of the company’s stock after selling 23,999 shares during the period. […] - 2025-04-28 05:01:20
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Legal & General Group Plc: Legal & General Group Plc trimmed its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 2.1% during the fourth quarter, Holdings Channel reports. The fund owned 26,595 shares of the company’s stock after selling 560 shares during the quarter. Legal & General Group Plc’s holdings in Tarsus Pharmaceuticals were worth $1,473,000 […] - 2025-04-27 05:42:58
Wells Fargo & Company MN Has $3.16 Million Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Wells Fargo & Company MN raised its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 44.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,004 shares of the company’s stock after buying an additional 17,451 shares during the period. […] - 2025-04-24 04:32:51
Geode Capital Management LLC Buys 3,014 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Geode Capital Management LLC lifted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 838,804 shares of the company’s stock after buying an additional 3,014 shares during the quarter. Geode […] - 2025-04-15 05:00:56
Pictet Asset Management Holding SA Invests $284,000 in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Pictet Asset Management Holding SA bought a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 5,130 shares of the company’s stock, valued at approximately $284,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of the […] - 2025-04-11 06:24:52
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Vanguard Group Inc.: Vanguard Group Inc. boosted its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 0.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,115,162 shares of the company’s stock after buying an additional 17,839 shares during the period. Vanguard Group Inc. owned 0.06% of Tarsus Pharmaceuticals worth $117,117,000 as […] - 2025-04-09 04:42:52
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up After Strong Earnings: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $45.54, but opened at $47.44. Tarsus Pharmaceuticals shares last traded at $44.83, with a volume of 251,757 shares. The company reported ($0.60) earnings per share […] - 2025-02-27 05:10:47
Allspring Global Investments Holdings LLC Has $10.03 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Allspring Global Investments Holdings LLC cut its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,122 shares of the company’s stock after selling 29,409 shares during the period. Allspring […] - 2025-02-19 07:08:18
Bleakley Financial Group LLC Makes New $323,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS): Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) in the fourth quarter, Holdings Channel reports. The firm bought 5,825 shares of the company’s stock, valued at approximately $323,000. A number of other large investors have also recently added to or reduced their stakes in the […] - 2025-02-12 06:57:10
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Buy” from Brokerages: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the […] - 2025-02-12 04:40:57
Tarsus Pharmaceuticals (NASDAQ:TARS) Given Buy Rating at Guggenheim: Guggenheim reissued their buy rating on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a research report released on Monday morning,Benzinga reports. A number of other equities analysts have also weighed in on the stock. Barclays boosted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an […] - 2025-02-11 05:09:04

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc TARS holdings

Date	Number of TARS Shares Held	Base Market Value of TARS Shares	Local Market Value of TARS Shares	Change in TARS Shares Held	Change in TARS Base Value	Current Price per TARS Share Held	Previous Price per TARS Share Held
2025-09-26 (Friday)	9,712	USD 546,688	USD 546,688
2025-09-25 (Thursday)	9,712	USD 537,948	USD 537,948	0	USD 1,263	USD 55.39	USD 55.26
2025-09-24 (Wednesday)	9,712	USD 536,685	USD 536,685
2025-09-17 (Wednesday)	9,650	USD 498,809	USD 498,809	0	USD 10,519	USD 51.6901	USD 50.6
2025-09-16 (Tuesday)	9,650	USD 488,290	USD 488,290
2025-09-12 (Friday)	9,588	USD 473,264	USD 473,264
2025-09-11 (Thursday)	9,588	USD 497,330	USD 497,330

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of TARS by Blackrock for IE00B3VWM098

Show aggregate share trades of TARS

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -31 56.560* 46.16 Profit of 1,431 on sale
2025-07-31 BUY 93 38.820* 46.15
2025-07-28 SELL -31 41.750* 46.25 Profit of 1,434 on sale
2025-06-30 SELL -62 40.510* 46.84 Profit of 2,904 on sale
2025-06-25 SELL -31 40.200* 46.97 Profit of 1,456 on sale
2025-06-20 SELL -62 40.650* 47.11 Profit of 2,921 on sale
2025-05-23 BUY 31 42.980* 47.92
2025-05-19 SELL -31 45.010* 48.05 Profit of 1,490 on sale
2025-05-15 SELL -93 43.500* 48.13 Profit of 4,476 on sale
2025-05-12 SELL -31 44.200* 48.27 Profit of 1,496 on sale
2025-05-09 SELL -31 44.760* 48.30 Profit of 1,497 on sale
2025-04-30 SELL -31 51.910* 48.30 Profit of 1,497 on sale
2025-04-24 SELL -62 49.970* 48.23 Profit of 2,990 on sale
2025-04-17 SELL -31 49.250* 48.17 Profit of 1,493 on sale
2025-04-15 SELL -93 49.120* 48.15 Profit of 4,478 on sale
2025-04-14 SELL -93 48.720* 48.14 Profit of 4,477 on sale
2025-04-09 SELL -124 45.870* 48.23 Profit of 5,981 on sale
2025-04-07 SELL -217 47.490* 48.28 Profit of 10,477 on sale
2025-04-04 SELL -310 47.020* 48.30 Profit of 14,972 on sale
2025-03-31 BUY 31 51.370* 48.21
2025-03-19 SELL -62 49.550* 47.93 Profit of 2,972 on sale
2025-03-14 SELL -186 48.090* 47.96 Profit of 8,921 on sale
2025-03-13 SELL -62 46.470* 47.98 Profit of 2,975 on sale
2025-03-12 SELL -1,054 47.100* 47.99 Profit of 50,585 on sale
2025-03-07 SELL -62 46.470* 48.08 Profit of 2,981 on sale
2025-03-06 SELL -93 43.570* 48.15 Profit of 4,478 on sale
2025-03-03 SELL -31 42.720* 48.36 Profit of 1,499 on sale
2025-02-28 SELL -45,552 44.480* 48.42 Profit of 2,205,576 on sale
2025-02-26 SELL -151 42.560* 48.60 Profit of 7,339 on sale
2025-02-25 SELL -453 41.290* 48.73 Profit of 22,073 on sale
2025-02-18 BUY 755 50.850* 48.75
2025-02-13 BUY 151 52.230* 48.62
2025-02-12 BUY 151 52.330* 48.54
2025-02-11 BUY 453 51.220* 48.49
2025-02-06 BUY 1,359 53.320* 48.21
2025-01-27 BUY 151 51.450* 47.10
2024-12-30 BUY 755 54.700* 46.51
2024-12-06 BUY 604 51.790* 46.06
2024-12-05 BUY 151 50.320* 45.92
2024-12-04 BUY 755 51.640* 45.71
2024-11-29 BUY 755 52.450* 45.07
2024-11-27 BUY 604 50.840* 44.56
2024-11-26 BUY 151 49.660* 44.33
2024-11-25 SELL -10,543 48.320* 44.14 Profit of 465,398 on sale
2024-11-21 BUY 915 46.400* 43.81
2024-11-20 BUY 549 46.580* 43.65
2024-11-18 BUY 2,196 44.630* 43.39
2024-11-12 BUY 1,464 47.570* 43.11
2024-11-08 BUY 915 49.420* 42.66
2024-11-07 BUY 2,730 46.790* 42.34
2024-11-06 BUY 364 46.800* 41.97
2024-10-31 BUY 182 44.490* 40.00
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-31	56.560*	46.16 Profit of 1,431 on sale
2025-07-31	BUY	93	38.820*	46.15
2025-07-28	SELL	-31	41.750*	46.25 Profit of 1,434 on sale
2025-06-30	SELL	-62	40.510*	46.84 Profit of 2,904 on sale
2025-06-25	SELL	-31	40.200*	46.97 Profit of 1,456 on sale
2025-06-20	SELL	-62	40.650*	47.11 Profit of 2,921 on sale
2025-05-23	BUY	31	42.980*	47.92
2025-05-19	SELL	-31	45.010*	48.05 Profit of 1,490 on sale
2025-05-15	SELL	-93	43.500*	48.13 Profit of 4,476 on sale
2025-05-12	SELL	-31	44.200*	48.27 Profit of 1,496 on sale
2025-05-09	SELL	-31	44.760*	48.30 Profit of 1,497 on sale
2025-04-30	SELL	-31	51.910*	48.30 Profit of 1,497 on sale
2025-04-24	SELL	-62	49.970*	48.23 Profit of 2,990 on sale
2025-04-17	SELL	-31	49.250*	48.17 Profit of 1,493 on sale
2025-04-15	SELL	-93	49.120*	48.15 Profit of 4,478 on sale
2025-04-14	SELL	-93	48.720*	48.14 Profit of 4,477 on sale
2025-04-09	SELL	-124	45.870*	48.23 Profit of 5,981 on sale
2025-04-07	SELL	-217	47.490*	48.28 Profit of 10,477 on sale
2025-04-04	SELL	-310	47.020*	48.30 Profit of 14,972 on sale
2025-03-31	BUY	31	51.370*	48.21
2025-03-19	SELL	-62	49.550*	47.93 Profit of 2,972 on sale
2025-03-14	SELL	-186	48.090*	47.96 Profit of 8,921 on sale
2025-03-13	SELL	-62	46.470*	47.98 Profit of 2,975 on sale
2025-03-12	SELL	-1,054	47.100*	47.99 Profit of 50,585 on sale
2025-03-07	SELL	-62	46.470*	48.08 Profit of 2,981 on sale
2025-03-06	SELL	-93	43.570*	48.15 Profit of 4,478 on sale
2025-03-03	SELL	-31	42.720*	48.36 Profit of 1,499 on sale
2025-02-28	SELL	-45,552	44.480*	48.42 Profit of 2,205,576 on sale
2025-02-26	SELL	-151	42.560*	48.60 Profit of 7,339 on sale
2025-02-25	SELL	-453	41.290*	48.73 Profit of 22,073 on sale
2025-02-18	BUY	755	50.850*	48.75
2025-02-13	BUY	151	52.230*	48.62
2025-02-12	BUY	151	52.330*	48.54
2025-02-11	BUY	453	51.220*	48.49
2025-02-06	BUY	1,359	53.320*	48.21
2025-01-27	BUY	151	51.450*	47.10
2024-12-30	BUY	755	54.700*	46.51
2024-12-06	BUY	604	51.790*	46.06
2024-12-05	BUY	151	50.320*	45.92
2024-12-04	BUY	755	51.640*	45.71
2024-11-29	BUY	755	52.450*	45.07
2024-11-27	BUY	604	50.840*	44.56
2024-11-26	BUY	151	49.660*	44.33
2024-11-25	SELL	-10,543	48.320*	44.14 Profit of 465,398 on sale
2024-11-21	BUY	915	46.400*	43.81
2024-11-20	BUY	549	46.580*	43.65
2024-11-18	BUY	2,196	44.630*	43.39
2024-11-12	BUY	1,464	47.570*	43.11
2024-11-08	BUY	915	49.420*	42.66
2024-11-07	BUY	2,730	46.790*	42.34
2024-11-06	BUY	364	46.800*	41.97
2024-10-31	BUY	182	44.490*	40.00

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of TARS

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	252,801	0	426,166	59.3%
2025-09-18	137,976	0	230,324	59.9%
2025-09-17	350,436	5	543,379	64.5%
2025-09-16	169,762	23	341,917	49.7%
2025-09-15	188,220	0	351,011	53.6%
2025-09-12	173,824	19	536,802	32.4%
2025-09-11	254,169	0	587,029	43.3%
2025-09-10	130,049	21,726	202,273	64.3%
2025-09-09	81,081	0	152,616	53.1%
2025-09-08	127,262	13,834	268,329	47.4%
2025-09-05	111,598	0	279,260	40.0%
2025-09-04	157,740	6,413	224,745	70.2%
2025-09-03	72,242	1,200	191,629	37.7%
2025-09-02	219,449	0	325,874	67.3%
2025-08-29	62,133	0	140,050	44.4%
2025-08-28	50,541	0	159,808	31.6%
2025-08-27	36,919	0	92,543	39.9%
2025-08-26	63,628	0	154,058	41.3%
2025-08-25	72,109	0	148,872	48.4%
2025-08-22	80,786	0	201,829	40.0%
2025-08-21	73,646	0	231,979	31.7%
2025-08-20	93,401	891	221,733	42.1%
2025-08-19	42,418	0	137,197	30.9%
2025-08-18	116,541	20,164	304,699	38.2%
2025-08-15	133,688	400	335,133	39.9%
2025-08-14	81,791	328	173,473	47.1%
2025-08-13	119,902	0	340,392	35.2%
2025-08-12	113,528	0	262,067	43.3%
2025-08-11	247,112	200	586,919	42.1%
2025-08-08	164,594	0	266,105	61.9%
2025-08-07	425,029	300	765,615	55.5%
2025-08-06	173,644	39	252,868	68.7%
2025-08-05	89,019	5	111,443	79.9%
2025-08-04	104,357	20	207,097	50.4%
2025-08-01	273,972	0	370,178	74.0%
2025-07-31	170,413	0	271,101	62.9%
2025-07-30	92,228	0	317,929	29.0%
2025-07-29	142,684	0	285,141	50.0%
2025-07-28	123,438	31	191,764	64.4%
2025-07-25	123,025	336	162,520	75.7%
2025-07-24	122,485	10	171,350	71.5%
2025-07-23	115,791	0	149,653	77.4%
2025-07-22	84,089	10	133,731	62.9%
2025-07-21	196,108	151	244,905	80.1%
2025-07-18	290,801	482	509,804	57.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE